Download this article to learn how one cell therapy manufacturer optimized PCR-based Mycoplasma testing for in-house use, ...

Abstract: This paper presents a method based on frequency shift feedback for living cell manipulation and in situ nano-injection with a cantilevered micropipette probe (CMP). This method can detect ...

NADES treatments significantly boost essential oil yield and antibacterial activity in Zanthoxylum bungeanum, offering a ...

Orionis to receive $105 million upfront, as well as future milestone-related payments. Orionis will leverage its Allo-Glue™ platform for the discovery of small-molecule monovale ...

"We are excited to be entering into this collaboration with Synfini to accelerate drug discovery around a publicly available high-value target,” said Helena Mancebo, CEO of Multispan. "By using ...

Corporate and Financial Updates In April 2025, Invivyd secured a $30 million non-dilutive term loan facility with Silicon Valley Bank, a division of First Citizens Bank, supporting balance sheet ...

Approaches for quick and sensitive profile of viral avidity toward a specific type of host cell glycan can contribute to the understanding of tropism switching among different IVA strains. Here, we ...

This review explores recent advances in the characteristics and manufacturing of CAR T-cell products. Traditional potency assays have been designed based on well-established CAR T-cell functionalities ...

Traditional methods for AAV potency testing, such as Western blot, ELISA, and cell-based assays, are labor-intensive and often limited in sensitivity and throughput. The Leo™ System, powered by ...

a new class of biomarker cell mimics specifically designed for functional CAR-T potency assays. TruCytes Potency cell mimics offer a customizable, scalable, and efficient alternative to cell line ...

During the oral presentation “Cell Mimics As High Precision Controls for CGT Analytics and Potency Assays” Robyn Hall ... before making any decisions based on such content.

The Boston-based company is advancing a robust clinical pipeline of assets across more than 10 indications. Candidates include zimislecel, an allogeneic beta-cell-based treatment for Type 1 ...